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Research on comorbidity and multimorbidity is fi nally 
receiving the attention it deserves, particularly consider-
ing the magnitude and impact they have on health and 
the delivery of healthcare [1, 2]. Numerous studies have 
demonstrated that individuals with Down’s syndrome, 
Parkinson’s disease, schizophrenia, diabetes, anorexia 
nervosa, Alzheimer’s disease, allergy related diseases, 
multiple sclerosis or Huntington’s disease (among other 
health problems) are protected against many forms of 
cancer, including solid tumors, smoking-related tumors 
and prostate cancer. This apparent anti-cancer effect, 
which we have termed inverse cancer comorbidity, has been 
observed in many serious CNS and immune disorders, 
and is the subject of active research [3–5]. 
Paradoxical nature of inverse comorbidity
While paradoxes are concepts that violate common 
sense, they have been an important source of inspiration 
and scientifi c progress in logic, mathematics, physics and 
economics. For example, the Viennese mathematician 
Kurt Gödel’s (1906–1978) Theorem of Incompleteness 
in Arithmetic stated that all mathematical systems have 
propositions that are impossible to prove or reject, thus 
affi rming the limited and incomplete nature of mathe-
matical knowledge. Gödel’s incompleteness theorem has 
infl uenced fi elds beyond mathematics and logic, contribu-
ting to the development of computational machines and 
theory of mind, among others [6]. Counterintuitive real-
ities also have a long tradition in biology, medicine and 
other life sciences. An example of one such peculiarity 
in immunology is the presence of “elite controllers” – 
rare individuals infected with human immunodefi -
ciency virus (HIV) whose immune systems are capable 
of spontaneously controlling HIV-1 replication for 
decades without the assistance of antiretroviral medica-
tion. Indeed, for a long time the existence of these elite 
controllers was considered proof that acquired immu-
nodefi ciency syndrome (AIDS) was not viral. In recent 
years, various genome-wide association studies (GWAS) 
have demonstrated that polymorphism within the 
human leukocyte antigen (HLA) class I locus is the pri-
mary host genetic determinant of the rate of progression 
of HIV infection to AIDS – which explains the dramatic 
differences observed in untreated disease outcome [7, 8]. 
A deeper understanding of innate immunity and early 
immune responses to HIV-1 could lead to the develop-
ment of an effective HIV-1 vaccine [9, 10]. 
Another example of a medical paradox relates to 
supercentenarians. These people, who live to the 
age of at least 110, are exceedingly rare: a mere seven 
of every 1,000 people reach the century milestone in 
industrialized countries [11, 12], and only 70 supercen-
tenarians (of whom 65 are women) have been validated 
worldwide by the Los Angeles Gerontology Research 
Group [13]. Given that genetic contribution is more 
pronounced at an older age, exceptional longevity and 
healthspan may be attributable to disease-associated 
and protective variants in the genome [14]. Longevity 
genes encode proteins involved in biological processes, 
including lipid-protein metabolism (e.g. apolipoprotein 
E); signaling of growth hormone 1/insulin-like growth 
factor 1/insulin; DNA damage, signaling, and repair; 
and pro/antioxidant pathways [15]. These molecular 
mechanisms also have a pivotal function in cancer and 
neurodegeneration. In this way, supercentenarians may 
be the key to a better understanding not only of the 
biological and non-biological determinants of longevity 
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but also of cancer and CNS disorders; knowledge that 
could be used to improve the quality of life of people in 
their latter years.
The traditional understanding of diseases in dichot-
omous (present versus absent), and hence, opposing 
terms, has led medical practice to focus on specifi c diag-
nostic categories or groups of disorders with overlapping 
phenotypes or pathophenotypes (e.g. neurodegenera-
tive disorders with the same cognitive impairments). 
Although this reductionist view is practical at a clinical 
level, it ignores the fact that the boundaries between dis-
eases are blurred in terms of genetics or proteomics [16]. 
By contrast, the more contemporary, cross-sectional 
perspective of disease–disease associations (positive or 
direct comorbidities) and counter-associations (inverse 
comorbidities) is based on the premise that the causes 
and pathogenic mechanisms of medical conditions 
are common to multiple categories. This viewpoint 
has led to the development of a highly valuable net-
work of disorders (phenotypic comorbidity network) 
[17, 18]. Moreover, several systems studies have discov-
ered novel disease associations based on either shared 
disease-causing genes or overlapping pathways [19]. For 
example, genetic susceptibility to seven autoimmune 
and infl ammatory (immune-mediated) diseases (celiac 
disease, Crohn’s disease, multiple sclerosis, psoriasis, 
rheumatoid arthritis, systemic lupus erythematosus, and 
type 1 diabetes) accounts for 47 of 107 (44%) immune-
mediated–disease risk single-nucleotide polymorphisms 
(SNPs) [20, 21]. This fi nding might explain why these 
disorders co-exist in certain populations. Evidence from 
studies examining association, gene expression and 
endophenotype have identifi ed at least three risk genes 
located on chromosome 8p (NRG1, DPYSL2, PPP3CC) 
affecting the expression of specifi c phenotypes – includ-
ing those of autism, schizophrenia, Alzheimer’s disease, 
Parkinson’s disease, prostate cancer and several types of 
epithelial cancers (breast, pancreatic and colon) – across 
the nosological boundaries [3–5]. Therefore, network 
methods that integrate different genetic, proteomic and 
metabolic datasets related to comorbidities (or spanning 
more than one disease) are likely to not only improve 
our understanding of disease etiology and of phenotype-
biomarker-genotype associations [16] but also help build 
a bridge between medical disciplines by promoting sci-
entifi c integration. 
We believe that inverse comorbidity represents an 
unprecedented opportunity to gain insight into the 
pathogenesis of many serious diseases, and that under-
standing why certain individuals diagnosed with specifi c 
disorders are protected against other medical conditions 
could help to develop new and improved treatments 
[5, 22].
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